Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Zhen-Wei Cai

Robert Michael Borzilleri

Rajeev S Bhide

Ligang Qian

Stephanie Barbosa

Kyoung S Kim

Louis John Lombardo

Jeffrey A Robl

John S Tokarski

Gretchen M Schroeder

Donna Wei

Junying Fan

Peter Zheng

Kap-Sun Yeung

Wayne D Vaccaro

Xiao-Tao Chen

Andrew J Tebben

Liping Zhang

Tram N Huynh

William P Gallagher

Heidi L Perez

Gerard Crispino

Francis S Gibson

Luca Parlanti

Zhong Chen

Robert C Livingston

Donna D Wei

Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds. 

Substituted sulfonamides useful as antiapoptotic Bcl inhibitors

Disclosed herein is a process for preparing a compound of Formula (I), comprising the steps of: (a) reacting an aniline compound of Formula (II) and an carboxylic acid compound of Formula (III) or an activated carboxylic acid compound thereof, to provide a compound of Formula (IV); and (b) converting said protected amine group attached to said compound of Formula (IV) to an amine group to provide said compound of Formula (I); wherein PAm is a protected amine group. Processes to prepare the compounds of Formulae (II), (III), and (IV) are also disclosed. 

4-pyridinone compounds and their use for cancer

The invention is directed to pyridinone compounds useful for modulating Met kinase, having the following structure: and is further directed to pharmaceutical compositions comprising the compound; and methods for treating proliferative diseases, such as cancer by the administration of this compound.

Pyridinone compounds

The present invention provides compound of Formula (I): or a stereoisomer, tautomer, salt or solvate thereof, wherein the variables are defined herein. The compounds of formula (I) are inhibitors of Bcl-2 family antiapoptotic proteins, compositions containing the compounds and methods of treating diseases using the compounds. 

Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors

Disclosed are compounds of Formula (I): and salts thereof. Also, disclosed are methods of using the compounds in the treatment of proliferative diseases, such as cancer, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a pharmaceutically acceptable salt.

The invention is directed to compounds that are useful for the treatment of cancer having the following Formula: 

Met kinase inhibitors

The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Inhibitors of kinases

The compounds of the instant invention can be used as anticancer agents. More specifically, the invention comprises a compound having Formula I or II, 

Bicyclic heterocycles as kinase inhibitors

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Heterocyclic inhibitors of kinases

In general, the instant invention comprises compounds of Formulas I and II including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.

Fused heterocyclic kinase inhibitors

The present invention is directed to intermediates that are useful for preparing pyrrolotriazines, and processes for preparing such intermediates.

Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors

In general, the instant invention comprises compounds having Formulae I and II: including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.

Growing community of inventors

Belle Mead, NJ, United States of America

Zhen-Wei Cai